详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China [2]China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China [3]China Med Univ, Coll Basic Med Sci, Shenyang, Peoples R China [4]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [5]Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [6]Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Fuzhou, Peoples R China [7]Shandong Univ, Qilu Hosp, Jinan, Peoples R China

出处：

ISSN：

关键词： BRAF V600E Immunohistochemistry Lung cancer

语种：

WOS：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 21.1 出版当年[2023版] 16.5 出版当年五年平均 20.4 出版前一年[2022版]

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Multiplex Immunohistochemistry Staining for Paraffin-embedded Lung Cancer Tissue [2]Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII) [3]Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC [4]非小细胞肺癌BRAF V600E突变免疫组织化学检测中国专家共识 [5]Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients [6]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report [7]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [8]Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer [9]BRAF V600E与TERT启动子共同突变在甲状腺乳头状癌诊治中的临床意义 [10]Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.